These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The problem of adverse drug reactions. Wintrobe MM JAMA; 1966 May; 196(5):404-5. PubMed ID: 5952216 [No Abstract] [Full Text] [Related]
3. The present status of adverse drug reaction reporting. Weston JK JAMA; 1968 Jan; 203(1):35-7. PubMed ID: 5694081 [No Abstract] [Full Text] [Related]
5. Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System. Friedman GD; Collen MF; Harris LE; Van Brunt EE; Davis LS JAMA; 1971 Aug; 217(5):567-72. PubMed ID: 5109088 [No Abstract] [Full Text] [Related]
7. The American Medical Association Registry on Adverse Reactions. De Nosaquo N Ann Intern Med; 1966 Jun; 64(6):1325-7. PubMed ID: 5952387 [No Abstract] [Full Text] [Related]
8. Discovering adverse drug reactions. Lasagna L JAMA; 1983 Apr 22-29; 249(16):2224-5. PubMed ID: 6339764 [No Abstract] [Full Text] [Related]
9. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system. Rossi AC; Knapp DE JAMA; 1984 Aug 24-31; 252(8):1030-3. PubMed ID: 6748207 [TBL] [Abstract][Full Text] [Related]
10. Council on drugs. To label or not to label. JAMA; 1965 Dec; 194(12):1311. PubMed ID: 5898088 [No Abstract] [Full Text] [Related]
11. AMA registry on adverse drug reactions. De Nosaquo N J Am Pharm Assoc; 1966 Feb; 6(2):66-8. PubMed ID: 5951869 [No Abstract] [Full Text] [Related]
12. Safety concerns at the FDA. Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696 [No Abstract] [Full Text] [Related]
13. The obituary of an idea. Moser RH JAMA; 1971 Jun; 216(13):2135-6. PubMed ID: 5108678 [No Abstract] [Full Text] [Related]
14. The Food and Drug Administration's role in promoting consistent labels for generic drugs. Duke JD; Kesselheim AS JAMA Intern Med; 2014 Aug; 174(8):1213-4. PubMed ID: 24957047 [No Abstract] [Full Text] [Related]
15. Improving detection of adverse effects of marketed drugs. Klein DF; O'Brien CP JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895 [No Abstract] [Full Text] [Related]
16. Reporting drug side effects: signals and noise. Avorn J JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853 [No Abstract] [Full Text] [Related]
17. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. Qato DM; Alexander GC JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303 [No Abstract] [Full Text] [Related]
18. Is the FDA going easy on violators? Lancet; 2006 Jul; 368(9530):92. PubMed ID: 16829277 [No Abstract] [Full Text] [Related]
19. Drug safety within drug use. Edlavitch SA; Salmon JW Dis Manag; 2006 Oct; 9(5):259-65. PubMed ID: 17044759 [No Abstract] [Full Text] [Related]
20. The role of litigation in defining drug risks. Kesselheim AS; Avorn J JAMA; 2007 Jan; 297(3):308-11. PubMed ID: 17227983 [No Abstract] [Full Text] [Related] [Next] [New Search]